Associated Papers
SEAP-GETNE consensus on prognostic and predictive molecular biomarkers in thyroid cancer.
Ruz-Caracuel I et al.
Revista Espanola De Patologia : Publicacion Oficial De La Sociedad Espanola De Anatomia Patologica Y De La Sociedad Espanola De Citologia, 2026
Design, synthesis, and activity evaluation of RET protein degradation based on PROTAC and HyTTD techniques.
Xu N et al.
Bioorganic & Medicinal Chemistry Letters, 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.
Waliany S et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2026
RET Gene Alterations in Clinical Practice: A Comprehensive Review and Database Update.
Ricciardi Tenore C et al.
Genes, 2025
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study.
Schöffski P et al.
Esmo Open, 2025
Discovery of APS03118, a Potent and Selective Next-Generation RET Inhibitor with a Novel Kinase Hinge Scaffold.
Zhong J et al.
Journal of Medicinal Chemistry, 2025
Discovery of an orally bioavailable, CNS active pan-mutant RET kinase heterobifunctional degrader.
Orsi DL et al.
Rsc Medicinal Chemistry, 2025
ENDOCAN-TUTHYREF network consensus recommendations. Refractory medullary thyroid cancer.
Lasolle H et al.
Annales D'endocrinologie, 2025
Circulating tumor DNA profiling for non-invasive genomic analysis in Indian lung cancer patients: A real-world experience.
Jha P et al.
The Journal of Liquid Biopsy, 2025
Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation.
Chung C et al.
Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners, 2025
Receptor Tyrosine Kinase Fusion-Mediated Resistance to EGFR TKI in EGFR-Mutant NSCLC: A Multi-Center Analysis and Literature Review.
Xia Y et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer, 2025
Resistance Mutation Profiles Associated with Current Treatments for Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung Cancer in the United States: A Systematic Literature Review.
Vadagam P et al.
Current Oncology (toronto, Ont.), 2025
Treatment of non-small cell lung cancer with RET rearrangements.
Hoe HJ et al.
Cancer, 2025
Discovery of a Selective and Orally Bioavailable RET Degrader with Effectiveness in Various Mutations.
Hualong M et al.
Journal of Medicinal Chemistry, 2025
Mechanisms of resistance to RET-directed therapies.
Clifton-Bligh RJ
Endocrine-related Cancer, 2025
Discovery of an Efficacious RET PROTAC Degrader with Enhanced Antiproliferative Activity against Resistant Cancer Cells Harboring RET Solvent-Front Mutations.
Zhang Q et al.
Journal of Medicinal Chemistry, 2025
BYS10, a novel selective RET inhibitor, exhibits potent antitumor activity in preclinical models.
Qin F et al.
Frontiers in Pharmacology, 2025
First-in-human, phase 1 dose-escalation and dose-expansion study of a RET inhibitor SY-5007 in patients with advanced RET-altered solid tumors.
Li W et al.
Signal Transduction and Targeted Therapy, 2024
MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer.
Wei X et al.
Cancer Letters, 2024
Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
Zhang Y et al.
Cell Communication and Signaling : Ccs, 2024
Side Chain Investigation of Imidazopyridazine as a Hinge Binder for Targeting Actionable Mutations of RET Kinase.
Maturi A et al.
Acs Medicinal Chemistry Letters, 2024
RET Inhibitors in RET Fusion-Positive Lung Cancers: Past, Present, and Future.
Chen MF et al.
Drugs, 2024
Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".
Spitaleri G et al.
Cancers, 2024
Afatinib as first-line treatment for advanced lung squamous cell carcinoma harboring uncommon EGFR G719C and S768I co-mutation: A case report and literature review.
Deng R et al.
Heliyon, 2024
Medullary Thyroid Cancer: Molecular Drivers and Immune Cellular Milieu of the Tumour Microenvironment-Implications for Systemic Treatment.
Papachristos AJ et al.
Cancers, 2024
Developing Dynamic Structure-Based Pharmacophore and ML-Trained QSAR Models for the Discovery of Novel Resistance-Free RET Tyrosine Kinase Inhibitors Through Extensive MD Trajectories and NRI Analysis.
Sayyah E et al.
Chemmedchem, 2024
RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.
Hamidi S et al.
Annales D'endocrinologie, 2024
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Wang ZX et al.
Journal of Medicinal Chemistry, 2024
Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing.
Tarasova VD et al.
Thyroid : Official Journal of the American Thyroid Association, 2024
Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China.
Pu X et al.
Thoracic Cancer, 2023
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.
Sahakian N et al.
Cancers, 2023
Medullary Thyroid Cancer: Updates and Challenges.
Gild ML et al.
Endocrine Reviews, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I et al.
Nature Cancer, 2023
Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive Lung Cancers.
Rotow J et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.
Khatri U et al.
Molecular Cancer Therapeutics, 2023
Progress and challenges in RET-targeted cancer therapy.
Hu X et al.
Frontiers of Medicine, 2023
Whole exome sequencing of 28 families of Danish descent reveals novel candidate genes and pathways in developmental dysplasia of the hip.
Dembic M et al.
Molecular Genetics and Genomics : Mgg, 2023
Medullary thyroid cancer - An update.
Fugazzola L
Best Practice & Research. Clinical Endocrinology & Metabolism, 2023
Targeting RET alterations in cancer: Recent progress and future directions.
Shabbir A et al.
Critical Reviews in Oncology/hematology, 2023
Blood Liquid Biopsy in an Advanced Medullary Thyroid Carcinoma: A Case Study with Rearranged during Transfection Heterogeneity.
Gumà J et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology, 2023
A comprehensive overview of the relationship between RET gene and tumor occurrence.
Zhao L et al.
Frontiers in Oncology, 2023